<DOC>
	<DOCNO>NCT03014115</DOCNO>
	<brief_summary>The clinical trial investigate effect different formulation ARA + 0.4 % DHA infant formula plasma fatty acid status healthy 6 month old infant supplement 6 month . A 6-month follow phase provide additional efficacy ( e.g . infection rate , immune marker ) safety information 12-18 month old infant .</brief_summary>
	<brief_title>Effects Different ARA Formulations Infant Formula Fatty Acid Status , Immune Markers Infection Rates Infants</brief_title>
	<detailed_description>This study randomize , double-blind , parallel-group study 0 % ARA +0.4 % DHA 0.76 % ARA +0.4 % DHA supplement infant formula provide 6 month old healthy infant 6 month . Infants breast-fed formula-fed prior enrollment . The difference total plasma fatty acid ARA level two group 6 month supplementation measure . Parents ask infant 's current daily diet ( fatty acid intake calculate via 24 hour recall ) . All complete infant enrol 6 month extension period ( non-supplemented ) collect additional measure efficacy ( i.e . infection illness , immune marker ) safety 18 month age .</detailed_description>
	<criteria>singleton infant , parent legal age consent , willing feed child assign study formula treatment duration , parent agrees schedule blood draw exclusively breastfed formulafed beyond 6 month , difficulty swallow congenital malformation metabolic anomaly , take omega3 ( supplement ) food , mother gestational diabetes Type II diabetic , bear &lt; 37 week gestational age , participate another study</criteria>
	<gender>All</gender>
	<minimum_age>22 Weeks</minimum_age>
	<maximum_age>26 Weeks</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>arachidonic</keyword>
	<keyword>docosahexaenoic acid</keyword>
	<keyword>infant formula</keyword>
</DOC>